Physician profile
Manuel Diaz
NPI 1689659062
$7,709.50
in general payments reported to CMS, 2019-2025
28 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $281 · 2021: $1,346 · 2022: $798 · 2023: $685 · 2024: $1,558 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,038.42 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $941.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $749.27 | 2021 | |
| Abbott Laboratories | $607.89 | 2022-2025 | Navitor, Amplatzer Talisman |
| Sanofi-Aventis U.S. LLC | $408.30 | 2019 | |
| Novo Nordisk INC | $370.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $341.96 | 2024-2025 | Symplicity G3, Onyx Frontier |
| Gilead Sciences, INC. | $335.11 | 2022-2025 | Biktarvy |
| Shionogi INC | $271.01 | 2023-2024 | Fetroja |
| Pfizer INC. | $242.20 | 2019-2025 | |
| Heartflow, INC. | $148.69 | 2025 | |
| Allergan, INC. | $125.62 | 2019 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $125.00 | 2025 | Nuzyra |
| Boston Scientific Corporation | $124.99 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $121.84 | 2024 | |
| Ferring Pharmaceuticals INC. | $121.81 | 2023 | Rebyota |
| Melinta Therapeutics, LLC | $115.96 | 2023 | Rezzayo |
| E.R. Squibb & Sons, L.L.C. | $110.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $57.05 | 2019-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $50.61 | 2024 | |
| Amneal Pharmaceuticals LLC | $48.33 | 2019-2025 | Unithroid |
| Lilly USA, LLC | $34.29 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Ibsa Pharma INC. | $22.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.02 | 2024 | Livalo |
| Exact Sciences Corporation | $17.79 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.